Wu B, Chen X, Cao C
Curr Oncol Rep. 2025; .
PMID: 39998781
DOI: 10.1007/s11912-025-01651-9.
Liao S, Zhang B, Su Y, Pan Y, Zhang J, Ye Z
Strahlenther Onkol. 2024; 200(10):867-875.
PMID: 38324078
DOI: 10.1007/s00066-024-02201-1.
Jiang Y, Huang S, Pan X, Ma J, Zhu X
Front Nutr. 2023; 10:1036572.
PMID: 36875852
PMC: 9977787.
DOI: 10.3389/fnut.2023.1036572.
Jiang Y, Liang Z, Chen K, Li Y, Yang J, Qu S
Eur Radiol. 2022; 33(3):2171-2184.
PMID: 36355201
DOI: 10.1007/s00330-022-09201-8.
Lien C, Wang C, Yang C, Wang C, Hwang T, Shih Y
Cancers (Basel). 2022; 14(18).
PMID: 36139674
PMC: 9496885.
DOI: 10.3390/cancers14184511.
Extraction parameter optimized radiomics for neoadjuvant chemotherapy response prognosis in advanced nasopharyngeal carcinoma.
Wang Y, Li C, Yin G, Wang J, Li J, Wang P
Clin Transl Radiat Oncol. 2022; 33:37-44.
PMID: 35024463
PMC: 8728047.
DOI: 10.1016/j.ctro.2021.12.005.
Usefulness of F-fluorodeoxyglucose positron-emission tomography/computed tomography combined with the platelet-lymphocyte ratio in predicting the prognosis of nasopharyngeal carcinoma.
Xian W, Feng Y, Wang Y, Yang M, Lu S
Br J Radiol. 2021; 95(1129):20210279.
PMID: 34813375
PMC: 8722261.
DOI: 10.1259/bjr.20210279.
The Relevance of Regenerating Gene 1a Polymorphisms to Radiation Sensitivity and Survival of Nasopharyngeal Carcinoma Receiving Radiotherapy in a Southern Chinese Population.
Xing H, Chen X, Sun H, Dai Y, Han Y, Chen H
Pharmgenomics Pers Med. 2021; 14:1403-1413.
PMID: 34785928
PMC: 8579874.
DOI: 10.2147/PGPM.S328285.
Retropharyngeal lymph node metastasis on N stage of nasopharyngeal carcinoma.
Pan X, Huang S, Qu S, Chen K, Jiang Y, Zhu X
PLoS One. 2021; 16(6):e0253424.
PMID: 34138943
PMC: 8211178.
DOI: 10.1371/journal.pone.0253424.
Identification of potential plasma biomarkers in early-stage nasopharyngeal carcinoma-derived exosomes based on RNA sequencing.
Zheng W, Ye W, Wu Z, Huang X, Xu Y, Chen Q
Cancer Cell Int. 2021; 21(1):185.
PMID: 33789676
PMC: 8011216.
DOI: 10.1186/s12935-021-01881-4.
The Usefulness of Pretreatment MR-Based Radiomics on Early Response of Neoadjuvant Chemotherapy in Patients With Locally Advanced Nasopharyngeal Carcinoma.
Yongfeng P, Chuner J, Lei W, Fengqin Y, Zhimin Y, Zhenfu F
Oncol Res. 2021; 28(6):605-613.
PMID: 33523792
PMC: 7962941.
DOI: 10.3727/096504020X16022401878096.
Effect of Induction Chemotherapy in Nasopharyngeal Carcinoma: An Updated Meta-Analysis.
Yang S, Guo J, Liu J, Liu Z, Chen E, Chen C
Front Oncol. 2021; 10:591205.
PMID: 33489889
PMC: 7820771.
DOI: 10.3389/fonc.2020.591205.
Optimal induction chemotherapeutic regimen followed by concurrent chemotherapy plus intensity-modulated radiotherapy as first-line therapy for locoregionally advanced nasopharyngeal carcinoma.
Wang F, Chuner J, Lei W, Fengqin Y, Zhimin Y, Quanquan S
Medicine (Baltimore). 2020; 99(39):e22283.
PMID: 32991429
PMC: 7523833.
DOI: 10.1097/MD.0000000000022283.
Staging of T2 and T3 nasopharyngeal carcinoma: Proposed modifications for improving the current AJCC staging system.
Cui C, Li H, Ma H, Dong A, Xie F, Liang S
Cancer Med. 2020; 9(20):7572-7579.
PMID: 32871059
PMC: 7571804.
DOI: 10.1002/cam4.3328.
Risk stratification for nasopharyngeal carcinoma: a real-world study based on locoregional extension patterns and Epstein-Barr virus DNA load.
Zhang L, Huang M, Fei-Xu , Wang K, Song D, Wang T
Ther Adv Med Oncol. 2020; 12:1758835920932052.
PMID: 32587634
PMC: 7294474.
DOI: 10.1177/1758835920932052.
Efficacy and safety of intensity-modulated radiotherapy alone versus intensity-modulated radiotherapy plus chemotherapy for treatment of intermediate-risk nasopharyngeal carcinoma.
Aftab O, Liao S, Zhang R, Tang N, Luo M, Zhang B
Radiat Oncol. 2020; 15(1):66.
PMID: 32178698
PMC: 7074987.
DOI: 10.1186/s13014-020-01508-4.
Influence of concurrent chemotherapy on locoregionally advanced nasopharyngeal carcinoma treated with neoadjuvant chemotherapy plus intensity-modulated radiotherapy: A retrospective matched analysis.
Wang F, Jiang C, Wang L, Yan F, Sun Q, Ye Z
Sci Rep. 2020; 10(1):2489.
PMID: 32051492
PMC: 7016014.
DOI: 10.1038/s41598-020-59470-w.
Survival without concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy plus intensity-modulated radiotherapy: Single-center experience from an endemic area.
Fangzheng W, Chuner J, Haiyan Q, Quanquan S, Zhimin Y, Tongxin L
Medicine (Baltimore). 2019; 98(51):e18484.
PMID: 31861031
PMC: 6940191.
DOI: 10.1097/MD.0000000000018484.
The primary lesion apparent diffusion coefficient is a prognostic factor for locoregionally advanced nasopharyngeal carcinoma: a retrospective study.
Huang T, Lu N, Lian S, Li H, Yin S, Geng Z
BMC Cancer. 2019; 19(1):470.
PMID: 31101029
PMC: 6525458.
DOI: 10.1186/s12885-019-5684-3.
Which induction chemotherapy regimen followed by cisplatin-based concurrent chemoradiotherapy is the best choice among PF, TP and TPF for locoregionally advanced nasopharyngeal carcinoma?.
He Y, Guo T, Wang J, Sun Y, Guan H, Wu S
Ann Transl Med. 2019; 7(5):104.
PMID: 31019954
PMC: 6462656.
DOI: 10.21037/atm.2019.02.15.